NCT03279601 is a Phase 2 clinical trial of Capecitabine, Dacarbazine in Neuroendocrine Tumors, sponsored by Peking University.

Who is sponsoring NCT03279601?

NCT03279601 is sponsored by Peking University.

What drugs are being tested in NCT03279601?

Interventions in NCT03279601: Capecitabine, Dacarbazine, Capecitabine, Temozolomide.

What condition does NCT03279601 study?

NCT03279601 studies Neuroendocrine Tumors.

Is NCT03279601 still recruiting?

NCT03279601 is currently status unknown. Last updated 12 September 2017.

Last reviewed 2017-09-12 · How we verify

NCT03279601

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor

Status unknown Phase 2 Last updated 12 September 2017

What this trial tests

Phase 2 trial testing Capecitabine, Dacarbazine in Neuroendocrine Tumors in 148 participants. Status unknown.

Timeline

1 September 2017

Primary endpoint
1 September 2019

1 September 2020

Quick facts

Lead sponsor	Peking University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	148
Start date	1 September 2017
Primary completion	1 September 2019
Estimated completion	1 September 2020
Sites	1 location across China

Drugs / interventions tested

Capecitabine, Dacarbazine — full drug profile →
Capecitabine, Temozolomide — full drug profile →

Conditions studied

Neuroendocrine Tumors — all drugs for Neuroendocrine Tumors →

Sponsor

Peking University

Who can join

18 and older, any sex, with Neuroendocrine Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will be conducted to compare the safety and efficacy of Capecitabine Combined With Dacarbazine(CAPDTIC) and Capecitabine Combined Temozolomide(CAPTEM) in advanced or metastatic gastrointestinal pancreatic and esophageal neuroendocrine tumor.In this prospective randomized phase II study, the investigators aim to compare the survival benefit as well as the safety forCapecitabine Combined With Dacarbazine(CAPDTIC) versus Capecitabine Combined Temozolomide(CAPTEM) in advanced or metastatic gastrointestinal pancreatic and esophageal neuroendocrine tumor.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.
Janmaat VT, Steyerberg EW, van der Gaast A, Mathijssen RH, et al · · 2017 · cited 74× · PMID 29182797 · DOI 10.1002/14651858.cd004063.pub4
Medical Treatment of Advanced Pancreatic Neuroendocrine Neoplasms.
Palmieri LJ, Dermine S, Barré A, Dhooge M, et al · · 2020 · cited 11× · PMID 32549203 · DOI 10.3390/jcm9061860
Efficacy and safety of temozolomide-based regimens in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis.
Taherifard E, Bakhtiar M, Mahnoor M, Ahmed R, et al · · 2024 · cited 6× · PMID 38347461 · DOI 10.1186/s12885-024-11926-2

Verify or expand the search:

Other recruiting trials for Neuroendocrine Tumors

Currently open trials in the same condition.

NCT07404176 — Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocr · Phase 2 · recruiting
NCT07314164 — Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment · recruiting
NCT07272512 — Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms · Phase 4 · recruiting
NCT06735560 — Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN · NA · recruiting
NCT06889493 — SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Dif · Phase 1 · recruiting

Other Peking University trials

Trials by the same sponsor.

NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03279601 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University
Last refreshed: 12 September 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03279601.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing